In a groundbreaking development for paediatric cancer care, Tata Memorial Hospital has introduced India’s inaugural liquid version of the chemotherapy drug 6-mercaptopurine, known as PREVALL. This innovative drug, developed in collaboration with Tata’s R&D arm Advanced Centre for Training Research and Education in Cancer (ACTREC) and IDRS Labs in Bangalore, marks a significant stride in treating blood-related cancers like Acute Lymphoblastic Leukaemia (ALL).
A Child-Friendly Alternative
The liquid formulation of PREVALL is poised to revolutionize paediatric ALL cases. Traditionally administered in tablet form, the liquid version offers a child-friendly alternative, simplifying the dosing process and potentially enhancing patient compliance.
Collaboration for Progress
The development of PREVALL is the result of a synergistic collaboration between Tata Memorial Hospital, ACTREC, and IDRS Labs in Bangalore. This partnership underscores the importance of collaborative efforts in advancing medical research and creating impactful solutions for critical health challenges.
Stability in Challenging Conditions
Experts highlight a crucial aspect of PREVALL – its stability in hot and humid conditions. The powder for the oral suspension is designed to maintain the drug’s stability, ensuring its effectiveness even in challenging weather conditions. This feature is particularly significant for regions with diverse climates.
CDSCO Approval and Nationwide Accessibility
The Central Drugs Standard Control Organisation (CDSCO) has granted approval for PREVALL, signifying its adherence to stringent quality and safety standards. Introduced at Tata Memorial Hospital in December, the liquid chemo drug is expected to become accessible in major hospital pharmacies across the country, providing a cutting-edge treatment option for paediatric cancer patients.
